 The study found that there is a lack of consensus among stakeholders regarding the best way to evaluate antibiotics, which can lead to delays in their approval and availability. This has been exacerbated by the fact that many countries have different approaches to evaluating antibiotics, making it difficult to predict when or if they will become available. Additionally, the study found that regulators and HTA agencies should work together to create more consistent standards for evaluating antibiotics, as well as explore new economic models to encourage the development of new antibiotics. This article was authored by Cecilia Kohlberg, Liv Matheson, Unigo Pinotten, and others.